Drug Utilization Review Board (DURB) Agenda

This meeting will be webcast. Members of the public may attend the meeting in person at the address above or access a live stream of the meeting here. Select the tab for the North Austin Complex Live on the date and time for this meeting. Please e-mail Webcasting@hhsc.state.tx.us if you have any problems with the webcasting function.

This meeting will also be conducted via videoconference call in accordance with the requirements of Section 551.127, Government Code. The member of the Board presiding over the meeting will be physically present at the location specified above.

Attendees who would like to provide public comment should see the Public Comment section below.

1. Call to order
2. Consideration of July 22, 2022, draft meeting minutes
3. Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL):
   1. Androgenic Agents, topical
   2. Antibiotics, gastrointestinal (GI)
   3. Antibiotics, topical
   4. Antibiotics, vaginal
   5. Anticonvulsants
   6. Antiemetic/Antivertigo Agents
   7. Antifungals, oral
   8. Antifungals, topical
   9. Antihistamines, first generation
   10. Antiparasitics, topical
   11. Antipsychotics
   12. Antivirals, topical
   13. Bone Resorption Suppression and Related Agents
   14. Colony Stimulating Factors
   15. Epinephrine, self-injected
   16. GI Motility, chronic
   17. Growth Hormone
   18. Hepatitis C Agents
   19. HIV / AIDS
   20. Hypoglycemics, incretin mimetics/enhancers
   21. Hypoglycemics, insulin and related agents
   22. Hypoglycemics, meglitinides
   23. Hypoglycemics, metformins
   24. Hypoglycemics, sodium-glucose cotransport-2 (SGLT2) inhibitors
   25. Hypoglycemics, thiazolidinediones (TZDs)
   26. Macrolides/Ketolides
   27. aa. Opiate dependence treatments
   28. bb. Tetracyclines
4. Public comment on single new drugs to be reviewed for the Medicaid PDL:
   1. Vonjo (oral)/ Oncology, oral - Hematologic  
   2. Tyvaso Dry Powder Inhaler (DPI) (inhalation) / Pulmonary Arterial Hypertension (PAH) agents, oral and inhaled
   3. Epsolay (topical) / Rosacea Agents, topical
   4. Quviviq (oral) / Sedative Hypnotics
5. Therapeutic and clinical drug reviews and updates:  Magellan Medicaid Administration
6. Executive work session
   
   Pursuant to Texas Government Code Section 531.071, and in accordance with Texas Administrative Code Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the DURB may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.
7. Announcements of drugs recommended for the Medicaid PDL: Magellan Medicaid Administration
8. Retrospective drug utilization review (DUR):  Conduent, LLC
   1. Recent interventions
      1. Migraine Disease Management
   2. Recent outcome reports
      1. Bipolar Disorder Management
      2. Diabetes Disease Management
      3. Influenza Prevention: vaccination and education (2021-2022)
   3. Potential RetroDUR interventions
      1. Hypertension Disease Management
      2. Management of Psychotropic Drugs in Adults
      3. Naloxone for High-Risk Patients
9. Prospective prior authorization proposals (clinical edits):  Kepro, LLC
   1. Androgenic Agents
      1. Jatenzo (testosterone undecanoate) – add new criteria
      2. Tlando (testosterone undecanoate) – add new criteria
      3. Add check for testosterone levels
   2. Anticonvulsant Agents
      1. Diacomit (stiripentol) - revised criteria
      2. Epidiolex (cannabidiol)  - revised criteria
      3. Fintepla (fenfluramine) – revised criteria
   3. Anxiolytics and Sedative/Hypnotics
      1. Lorazepam - revised criteria for under 2 years of age
   4. Vivjoa (oteseconazole) – new criteria
10. Retrospective drug use criteria for outpatient use in Vendor Drug Program:
    The University of Texas at Austin College of Pharmacy
    1. Anti-Diabetic Agents (oral)
    2. Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder Medications
    3. Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
    4. Pramlintide
    5. Serotonin 5-HT3 Receptor Antagonists for Nausea and Vomiting (oral)
    6. Substance P/Neurokinin1 Receptor Antagonists
11. Review of action items for next meeting:  Jan 20, 2023, 9:00 a.m.
12. Adjournment

The Board may take any action on any agenda item.

Public Comment: HHSC welcomes public comments pertaining to topics related to DURB and Medicaid PDL. Members of the public who would like to provide public comment may choose from the following options:

1. Oral comments provided virtually: Members of the public must pre-register to provide oral comments virtually during the meeting by completing a Public Comment Registration form and submitting a completed Public Comment Form, HHS Form 1320 no later than 5:00 p.m. Wednesday, October 19, 2022. Please mark the correct box on the Public Comment Registration form and provide your name, either the organization you are representing or that you are speaking as a private citizen, and your direct phone number. If you have completed the Public Comment Registration form, you will receive an email the day before the meeting with instructions for providing virtual public comment. Public comment is limited to three minutes. Each speaker providing oral public oral comments virtually must ensure their face is visible and their voice audible to the other participants while they are speaking. Each speaker providing oral public comment must state their name and on whose behalf they are speaking (if anyone). If you pre-register to speak and wish to provide a handout before the meeting, please submit an electronic copy in accessible PDF format with a completed Written Public Comment form, HHS Form 1334, that will be distributed by HHS staff to DURB members and State staff. Handouts are limited to two pages (paper size: 8.5” by 11”, one side only). Handouts must be emailed to VDP-Advisory@hhsc.state.tx.us immediately after pre-registering, but no later than 5:00 p.m. Wednesday, October 12, 2022, and include the name of the person who will be commenting. Do not include health or other confidential information in your comments or handouts. Staff will not read aloud handouts aloud during the meeting, but handouts will be provided to DURB members and State staff.
2. Written comments: Members of the public may provide written public comments by completing a Public Comment Registration form,  HHS Form 1334 at https://texashhsmeetings.org/DURB_PCReg_Oct2022. A member of the public who wishes to provide written public comments must email the comments to VDP-Advisory@hhsc.state.tx.us no later than 5:00 p.m. Wednesday, October 12, 2022. Please include your name and the organization you are representing or that you are speaking as a private citizen. Written comments must be emailed to HHSC immediately after pre-registering and include the name of the person who will be commenting. Written comments are limited to two pages (paper size: 8.5” by 11”, one side only). Do not include health or other confidential information in your comments. Staff will not read written comments aloud during the meeting, but comments will be provided to DURB members and State staff. 
3. Oral comments provided in-person at the meeting location: Members of the public may provide oral public comment during the meeting in person at the meeting location either by pre-registering using the form above or without pre-registering by completing a form at the entrance to the meeting room. Do not include health or other confidential information in your comments.

Note: These procedures may be revised at the discretion of HHSC.

Contact: Questions regarding agenda items, content, or meeting arrangements should be directed to Maribel O. Castoreno, DUR/PDL Oversight Specialist, Health and Human Services Commission, Medicaid and CHIP Services, 512-552-7672, and VDP-Advisory@hhsc.state.tx.us.

This meeting is open to the public.  No reservations are required, and there is no cost to attend this meeting.

Persons who want to attend the meeting and require assistive technology or services should contact Castoreno at 512-552-7672 or VDP-Advisory@hhsc.state.tx.us at least 72 hours before the meeting so appropriate arrangements can be made.